HIV Detail
News and Resources
Related Products
Selected References in Antivirals
Journal Articles
Rosario MC, Poland B, Sullivan J, Westby M, van der Ryst E. A Pharmacokinetic-Pharmacodynamic Model to Optimize the Phase IIa Development Program of Maraviroc. JAIDS. June 2006; 42:2.
Poland B, Wada R. Combining drug-disease and economic modelling to inform drug development decisions Drug Discovery Today. November 2001;6(22):1165-1170.
Conference Presentations & Posters
Poland B. PK/PD Modeling Shows Adherence Can Become Critical With New HCV Regimens. [invited presentation]. Presented at: 4th International Workshop on Clinical Pharmacology of Hepatitis Therapy; June 26-27, 2009; Boston, Massachusetts.
Poland B. Using in Vitro and Literature Data to Predict Effects of New Anti-Retrovirals. [invited presentation]. Presented at: ASCPT Annual Meeting; April 2-5, 2008; Orlando, Florida.
Keung A, Prasad P, Martinho M, Fellows K, Sansone A, O'Mara E, Dunkle L, Greaves W, Landovitz R, Poland W, Kuwabara-Wagg J. A Pharmacokinetic-Pharmacodynamic (PK-PD) Disease Model to Describe Antiviral Activity of Vicriviroc. [poster]. Presented at: 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 27-30, 2006; San Francisco, California.
Prins K, Poland B, Nicolas V, Porchet H, Scalfaro P, Bruno R. Modeling and Simulation of DEBIO-025 to Support Design of a Dose-Response Monotherapy Study in HIV-1 Infected Patients. [poster presentation]. Annual Meeting of the Population Approach Group in Europe (PAGE); June 2006; Bruges, Belgium.
Poland W, Bruno R, Hovde M, Wagg JK. Best Practices in Model-Based HIV Drug Development. [poster abstract P602]. Presented at: 16th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); April 2006; Nice, France.
Rosario MC, Jacqmin P, Poland W, Muirhead G, McFayden L. PK-PD-Disease Modelling and Simulation in the Development of Maraviroc (UK-427,857). Presented at 6th International Workshop on Clinical Pharmacology of HIV Therapy, Quebec, April 2005. Abstract 2. Publication in JAIDS pending.
Hawley P, Amantea M, Poland B, Hammond J, Raber S, Gao Y, Lertratanakul A, Wada R. Integrated Adherence, Pharmacokinetic, and Pharmacodynamic Modeling to Design a Dose-Ranging Study of Capravirine with Kaletra in Treatment-Experienced Patients [poster]. Presented at: 4th International Workshop on the Clinical Pharmacology of HIV Therapy; March 27-29, 2003; Cannes, France.
Amantea M, Raber S, Pesano R, Garrett M, Ballow C, Lertratanakul A, Poland B, Wada R. Pharmacokinetic Model of Capravirine (CPV), a Novel Non-Nucleoside Reverse Transcriptase Inhibitor, Co-Administered with Kaletra in Healthy and HIV-Infected Subjects. [poster]. Presented at: 4th International Workshop on the Clinical Pharmacology of HIV Therapy; March 27-29, 2003; Cannes, France.
Hsu A, Wada R, Poland B, et al. The Role of Pharmacokinetic/Pharmacodynamic Modeling in HIV Therapy. 9th Workshop on Advanced Methods of Pharmacokinetic & Pharmacodynamic Systems Analysis, 2001.
Hsu A, Wada R, Poland B, et al. PK/PD Modeling of ABT-378/Ritonavir Clinical Trials, Including an Adherence Factor. 7th Annual European Congress on Clinical Aspects and Treatment of HIV-Infection, 1999.